CONGRESS ABSTRACT

Introduction: Immune checkpoint inhibitors (ICIs) have successfully revolutionized cancer therapy, but their immune-mediated adverse events include rare, often severe myocarditis. While dual ICI blockade is associated with increased cardiotoxic risk, little is known about the potential effects of triplet combinations currently under clinical investigation. We developed a co-culture model…

Over the past decade, immune checkpoint inhibitors (ICIs) have dramatically transformed the treatment of several solid and hematologic malignancies. Despite their proven clinical benefit, ICIs are associated with immune-related adverse events (irAEs), among which cardiovascular toxicities are increasingly recognized as rare but potentially life-threatening complications. In particular, ICI-associated myocarditis…

Background: Cardiovascular toxicity could potentially limit anticancer therapy and its features encompassed many different clinical scenarios. Among others, cancer therapy–related cardiac dysfunction (CTRCD) with left ventricular (LV) systolic impairment could represent a major issue. CTRCD is frequently asymptomatic and often effectively treated with standard heart failure (HF) therapy. Limited…

Cardiotoxicity is a frequent and clinically relevant complication of cancer therapies and may result in heart failure, even years after oncological treatment. Anthracycline-containing regimens and chest radiotherapy are well-known contributors to cancer therapy–related cardiac dysfunction. Early recognition and optimization of heart failure therapy are essential to improve outcomes. Emerging…

Background : Fluoropyrimidines are the most commonly used drugs in the treatment of colorectal tumors. The fluoropyrimidine-related cardiotoxicity remains a major clinical problem. Purpose: The aim of this study was to evaluate the relationship between cardiotoxicity (CT) and Renal arterial Resistance Index (RRI) as marker of renal perfusion. Methods…

Introduction: Intracardiac metastasis from renal cell carcinoma (RCC) is an infrequent clinical finding. Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are associated with immune-related adverse events (irAEs). Among these, ICI-induced myocarditis is a rare but potentially fatal complication, typically occurring early after treatment initiation. However, vigilance must…